Stamford-based Cara Therapeutics Inc. (NASDAQ: CARA) is laying off part of its workforce in an effort to reduce operating costs while shifting its primary focus to developing a drug to treat notalgia paresthetica (NP), a neuropathic disorder for which here is no federally approved therapy.